CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China
SUZHOU, China, Nov. 19, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) today announced that a first patient has been enrolled and dosed in a Phase I clinical trial in China for…